期刊
JOURNAL OF INFECTIOUS DISEASES
卷 224, 期 -, 页码 S429-S442出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiab387
关键词
herpes zoster; zoster vaccine; live attenuated Oka varicella-zoster vaccine; recombinant zoster vaccine
资金
- Veterans Affairs (VA) Cooperative Studies Program
- James R. and Jesse V. Scott Fund for Shingles Research
- National Institute of Allergy and Infectious Diseases
Herpes zoster is a common virus that affects many people, and vaccines for preventing HZ and PHN are important for older adults. Clinical trials and real-world studies have shown that the vaccines are safe and effective in preventing these conditions.
Herpes zoster (HZ) affects approximately 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age. The most common, debilitating complication of HZ is the chronic neuropathic pain of postherpetic neuralgia (PHN). Two herpes zoster vaccines, a live-attenuated varicella-zoster virus (VZV) vaccine (zoster vaccine live [ZVL]; ZOSTAVAX [Merck]) and an adjuvanted VZV glycoprotein E (gE) subunit vaccine (recombinant zoster vaccine [RZV]; SHINGRIX [GlaxoSmithKline]) are licensed for the prevention of HZ and PHN in healthy older adults. The safety and efficacy of both vaccines has been demonstrated in clinical trials in immunocompetent adults and in selected immunocompromised persons and persons with immune-mediated diseases. Numerous real-world effectiveness studies have confirmed the safety and effectiveness of both ZVL and RZV. Recombinant zoster vaccine (RZV) is more effective for prevention of HZ than ZVL. Recombinant zoster vaccine is nonreplicating and is thus safe in immunocompromised persons. Additional zoster vaccines are in different stages of development. Wider distribution of safe and effective zoster vaccines will improve the health and well being of the rapidly growing population of older adults around the world.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据